Does the Texas Medical Board require a dedicated permit for storing allografts in an outpatient clinic?

The Texas Medical Board regulates physician conduct and standard of care rather than granting facility permits. However, practices receiving and storing human cellular and tissue-based products (HCT/Ps) must comply with Texas Department of State Health Services (DSHS) tissue distributor licensing requirements and FDA 21 CFR 1271 registration standards.

Can Physician Assistants or Nurse Practitioners administer allografts in Texas?

Yes, mid-level providers can administer allografts provided the delegating physician has established clear written protocols, standing delegation orders, and adequate supervision pursuant to TMB Rule 193. The treating physician retains ultimate medical responsibility for patient selection and treatment oversight.

How long must a practice retain tissue receipt, storage, and administration logs in Texas?

Tissue logs and associated clinical documentation should be maintained in alignment with Texas medical record retention rules, which generally require retaining adult patient records for at least seven years from the last date of treatment.

What standard operating procedure is required if an allograft freezer experiences a temperature excursion?

Practices must immediately quarantine the affected tissue, document the duration and peak temperature of the excursion, contact the vendor or manufacturer to determine product viability, and refrain from clinical use until formal authorization or disposition instructions are provided.

Texas Regulations for Storing & Administering Allografts

In Texas, outpatient medical practices storing and administering human tissue allografts must navigate regulations established by the Texas Medical Board (TMB) alongside Texas Department of State Health Services (DSHS) tissue bank rules and FDA 21 CFR 1271 standards. Compliant practice operation requires verified vendor licensing, strict ultra-low or controlled ambient temperature logs, complete chain-of-custody documentation from receiving to patient administration, and clear delegation protocols for clinical staff. Licensed physicians remain ultimately responsible for tissue traceability, informed consent, and ensuring all procurement originates from compliant distributors.

Texas Regulatory Landscape for Human Tissue Allografts

Integrating allogenic cellular and tissue-based products into a medical practice requires balancing federal biological regulations with state-level medical board oversight. The Food and Drug Administration (FDA) regulates human cells, tissues, and cellular and tissue-based products (HCT/Ps) under 21 CFR Part 1271. In Texas, the Texas Medical Board (TMB) establishes standards of care, delegation rules, and record-keeping mandates for licensed physicians utilizing these products.

Additionally, the Texas Department of State Health Services (DSHS) oversees tissue bank licensing within the state. Medical facilities that store, handle, or distribute tissue allografts must ensure their procurement partners hold appropriate DSHS tissue distributor licensing. Failing to maintain compliant procurement channels or precise storage documentation exposes practices to regulatory scrutiny, board inquiries, and professional liability risks.

For practice managers and compliance officers, maintaining alignment between vendor documentation, clinical delegation, and daily office standard operating procedures (SOPs) is essential when offering biologics such as amniotic allografts, cord blood tissue, or Wharton's jelly formulations.

Storage and Chain-of-Custody Compliance Checklist

To satisfy both TMB standard-of-care expectations and DSHS operational standards, practice administrators should establish a centralized compliance framework. Maintaining tissue integrity requires strict cold-chain maintenance from the moment a shipment arrives at the facility until the tissue is applied in a clinical procedure.

Essential Operational Checklist for Allograft Handling

Vendor License Verification: Verify that the biological distributor holds an active Texas DSHS Tissue Distributor License (e.g., license #1002308) and an active FDA Form 3356 registration prior to issuing purchase orders.
Receiving Protocol & Cold-Chain Inspection: Inspect all incoming shipments immediately for intact continuous temperature indicators (dry ice levels, temperature data loggers) and physical seal integrity. Document arrival time, ambient condition, and package lot numbers.
Dedicated Storage Equipment: Utilize medical-grade freezers or storage units equipped with continuous digital temperature monitoring and high/low threshold alarms. Standard commercial or kitchen freezers are insufficient for ultra-low (-80°C) or controlled sub-zero storage requirements.
Daily Temperature Logs: Maintain manual or automated digital temperature logs recorded twice daily (or continuously via validated telemetry systems). Records should include date, exact time, recorded temperature, and staff initials.
Quarantine Procedures: Establish a written SOP for temperature excursions. Any unit subjected to non-compliant temperature ranges must be immediately isolated in a tagged quarantine state and held until manufacturer quality assurance provides written disposition.
Lot Traceability Logbook: Log every tissue unit into a master inventory ledger detailing the manufacturer name, tissue product description, unique serial/lot number, expiration date, storage location, patient name, patient record number, and date of administration.

Practices implementing these protocols create an auditable defense against compliance audits while safeguarding tissue viability. You can review additional operational details on our FAQ page.

Clinical Administration and Delegation Guidelines

While practice managers focus on workflow, procurement, and storage records, treating clinicians must focus on patient assessment, delegatory compliance, and administration protocols.

Under TMB Rule 193, Texas physicians may delegate specific medical acts to qualified physician assistants (PAs), nurse practitioners (NPs), or other clinical personnel. However, the delegating physician retains ultimate responsibility for patient care, clinical appropriateness, and procedure oversight when using human allografts.

Clinical Responsibilities for Licensed Providers

Diagnostic Evaluation and Appropriateness: The treating provider must conduct a comprehensive medical evaluation to establish medical necessity for allograft placement, ensuring the patient's pathology matches the tissue product's regulatory intended use.
Informed Consent Protocol: Clinical consent forms must explicitly detail the nature of the allogenic tissue, donor screening processes, alternative treatments, potential risks, and expected therapeutic goals. Patients must understand that allografts derived from donor tissue are thoroughly screened according to FDA communicable disease standards.
Handling and Thawing Verification: Clinicians or clinical staff must follow exact manufacturer Instructions for Use (IFUs) regarding thawing, reconstitution, or rehydration. Improper thawing (e.g., incorrect water bath temperature or manual agitation) can compromise structural cellular scaffolding or protein integrity.
EHR Documentation and Traceability: Following application, the treating clinician must enter the exact tissue lot number, expiration date, volume/quantity injected or applied, anatomically precise application site, and any delegation details directly into the patient's electronic health record (EHR).

Clinicians seeking further insight into operational integration across specialty areas can explore resources tailored for regenerative medicine doctors.

Key Vendor Selection Criteria for Practice Administrators

Managing treatment costs and practice liability starts with selecting verified, compliant suppliers. Practice administrators should evaluate biological vendors against rigid legal and operational benchmarks rather than product claims alone.

When evaluating a distributor, practice managers should request and verify the following documentation:

Active Texas DSHS Tissue Distributor License
Current FDA Establishment Registration (Form 3356)
Product-specific Certificate of Analysis (CoA) for donor lot screening and sterility testing
Comprehensive tissue handling protocols and shipping temperature validation studies

Partnering with a fully licensed Texas distributor ensures that the practice maintains a compliant chain of custody from tissue recovery through delivery to the clinical facility. Learn more about regional distribution compliance on our about page.

What This Means for Your Practice

Navigating Texas Medical Board expectations and tissue regulations does not need to disrupt daily office efficiency. Practice managers and medical directors can protect their operation by executing four immediate action steps:

Audit Storage Hardware & Telemetry: Ensure all allograft storage freezers feature calibrated digital monitoring, continuous backup battery power, and automated alarm systems.
Review Standard Delegation Orders: Verify that written standing delegation orders for mid-level clinicians clearly delineate allograft handling, thawing, and administration protocols.
Update Inventory Tracking in EHR: Check that clinical templates capture mandatory lot number data, donor tracking identifiers, and precise anatomical application sites.
Validate Vendor Credentials: Audit current biological suppliers to confirm active Texas DSHS licensing and FDA tissue registration.

Establishing these operational safeguards ensures your facility maintains regulatory compliance, protects standard of care, and supports clinical safety across all service lines.

To review compliant tissue options, verify licensing, or consult on practice workflow integration, contact the distribution team at Dallas Regenerative Solutions by visiting our contact page.